The ARB telmisartan was found to be just as effective as the current gold standard ACE inhibitor ramipril at lowering CVD risk, delegates were told at the annual scientific American College of Cardiology in Chicago this month.
The ONTARGET study compared the effects of the two drugs on CVD risk in a group of 25,620 patients, over the age of 55, with CHD or diabetes.
Patients were randomly assigned to receive either ramipril 10mg daily, telmisartan 80mg daily or both for four years and seven months.
Telmisartan was found to be as equally effective at reducing CVD risk as ramipril. The ARB was also better tolerated with lower rates of cough.
However, a combination of an ARB and an ACE inhibitor offered no additional benefit and increased the risk of side effects such as syncope.
Primary Care Cardiovascular Society member Dr Sarah Jarvis said: 'Many patients on ACE inhibitors suffer from coughs, so a drug that has so few side-effects will be of huge importance to them.'